

# BRISTOL-MYERS SQUIBB CO.

ISIN: US1101221083 WKN: 110122108 Asset Class: Stock

## Company



2020/09/24 22:10:00

Price  
**58.25**  
USD

Difference ▼ -1.25% (-0.74)



## Contact Details

BRISTOL-MYERS SQUIBB CO. Tel: (212) 546-4000  
 -- Fax: (212) 546-4020  
 345 Park Avenue Web: <http://www.bms.com>  
 NY 10154 New York E-mail: -

## Company Profile

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2019		2018		2017	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	29,354,000,000		17,160,000,000		14,854,000,000	
<b>Common stock capital</b>		292,000,000		221,000,000		221,000,000
<b>Fixed assets</b>	-		-		-	
<b>Equity capital of a company</b>		51,598,000,000		14,031,000,000		11,741,000,000
<b>Cash and cash equivalents</b>	12,346,000,000		6,911,000,000		5,421,000,000	
<b>Accrued liabilities</b>		-		1,048,000,000		1,164,000,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		18,304,000,000		10,654,000,000		9,563,000,000
<b>Prepayments and accrued income</b>		-		-		-
<b>Non-current liabilities</b>		-		-		-
<b>Different income</b>		-		640,000,000		537,000,000
<b>Other liabilities</b>		-		-		-
<b>Total assets</b>	129,944,000,000	129,944,000,000	34,986,000,000	34,986,000,000	33,551,000,000	33,551,000,000

## Balance notes

	2019	2018	2017
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	30,000	23,300	23,700
<b>Equity ratio</b>	39.78%	40.38%	35.31%
<b>Debt-equity ratio</b>	151.35%	147.65%	183.20%

## Others

	2019	2018	2017
<b>Tax Expense Rate</b>	30.45%	17.11%	81.00%

# BRISTOL-MYERS SQUIBB CO.

ISIN: US1101221083 WKN: 110122108 Asset Class: Stock

## Income statement

	2019	2018	2017
Turnover	26,145,000,000	22,561,000,000	20,776,000,000
Net income	3,439,000,000	4,920,000,000	1,007,000,000
EBIT	4,229,247,500	5,073,396,800	4,361,863,100
Operating income before taxes	4,975,000,000	5,968,000,000	5,131,000,000
Cash Flow	8,067,000,000	5,940,000,000	5,275,000,000
Net interest income	-	-	-
Research and development expenses	6,148,000,000	6,345,000,000	6,411,000,000
Income taxes	1,515,000,000	1,021,000,000	4,156,000,000
Result from investments in subsidiaries, associates and other	-	-	-
Revenues per employee	740,862	823,138	745,218

## Board of Directors

## Members of Management Board

Giovanni Caforio	Chairman of Board of Directors
Theodore R. Samuels	Member of Board of Directors
Robert J. Bertolini	Member of Board of Directors
Phyllis Yale	Member of Board of Directors
Peter J. Arduini	Member of Board of Directors
Paula A. Price	Member of Board of Directors
Michael Bonney	Member of Board of Directors
Matthew W. Emmens	Member of Board of Directors
Karen H. Vousden	Member of Board of Directors
Gerald L. Storch	Member of Board of Directors
Dinesh C. Paliwal	Member of Board of Directors
Derica W. Rice	Member of Board of Directors
Vicki L. Sato	Member of Board of Directors
Julia A. Haller	Member of Board of Directors
Giovanni Caforio	Chairman of Managing Board
Severine Lacourt	Member of Executive Committee
Sandra Leung	Member of Executive Committee
Samit Hirawat	Member of Executive Committee
Rupert Vessey	Member of Executive Committee
Paul von Autenried	Member of Executive Committee
Nadim Ahmed	Member of Executive Committee
Lou Schmukler	Member of Executive Committee
Kathryn Metcalfe	Member of Executive Committee
Joseph E. Eid	Member of Executive Committee
Elizabeth A. Mily	Member of Executive Committee